These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24872678)

  • 21. Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration.
    Liu H; Yu N; Lu S; Ito S; Zhang X; Prasad B; He E; Lu X; Li Y; Wang F; Xu H; An G; Unadkat JD; Kusuhara H; Sugiyama Y; Sahi J
    Drug Metab Dispos; 2015 Jul; 43(7):1008-18. PubMed ID: 25908246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal absorption mechanism of rotundic acid: Involvement of P-gp and OATP2B1.
    Shang H; Sun Y; Wang Z; Zhou Y; Yang H; Ci X; Cui T; Xia Y; Gu Y; Liao M; Li Q; Si D; Liu C
    J Ethnopharmacol; 2022 May; 289():115006. PubMed ID: 35051604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periplocymarin is a potential natural compound for drug development: highly permeable with absence of P-glycoprotein efflux and cytochrome P450 inhibitions.
    Martey ON; He X; Xing H; Deng F; Feng S; Li C; Shi X
    Biopharm Drug Dispos; 2014 May; 35(4):195-206. PubMed ID: 24424534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
    Guo A; Marinaro W; Hu P; Sinko PJ
    Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
    Garver E; Hugger ED; Shearn SP; Rao A; Dawson PA; Davis CB; Han C
    Drug Metab Dispos; 2008 Dec; 36(12):2492-8. PubMed ID: 18755851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transporter-Mediated Drug-Drug Interactions and Their Significance.
    Liu X
    Adv Exp Med Biol; 2019; 1141():241-291. PubMed ID: 31571167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
    Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
    Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
    Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
    Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
    Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
    Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
    Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
    Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
    Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
    Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
    Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
    Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.